Table 1.
Baseline characteristics of study patients
| Parameters | Abexol (n = 22) | Atorvastatin (n = 23) | Combined therapy (n = 24) | Diet + exercise (n = 23) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years) (X ± SD) | 51 ±8 | 50 ±11 | 54 ±11 | 52 ±7 | |||||
| Body mass index (BMI) (kg/m2) | 31.5 ±4.9 | 30.9 ±4.9 | 29.4 ±3.7 | 30.0 ±3.7 | |||||
| Hip circumference (cm) | 106.4 ±8.9 | 107.4 ±12.2 | 106.8 ±12.6 | 102.7 ±11.2 | |||||
| Body weight (kg) | 83.8 ±14.9 | 82.7 ±16.2 | 81.9 ±14.9 | 84.1 ±15.0 | |||||
| Pulse (beats/min) | 76.4 ±9.2 | 77.7 ±7.4 | 74.2 ±8.5 | 78.2 ± 6.5 | |||||
| Diastolic blood pressure (mmHg) | 80.0 ±10.7 | 79.6 ±6.4 | 81.7 ±9.5 | 79.8 ±7.8 | |||||
| Systolic blood pressure (mmHg) | 123.6 ±10.9 | 124.8 ±9.9 | 127.9 ±16.1 | 126.5 ±11.5 | |||||
| Aspartate aminotransferase (U/l) | 30.9 ±10.7 | 38.5 ±21.1 | 29.7 ±14.3 | 33.3 ±13.8 | |||||
| Alanine aminotransferase (U/l) | 42.4 ±20.6 | 57.4 ±32.9 | 37.6 ±20.1 | 48.3 ±31.0 | |||||
| γ-glutamyl transferase (U/l) | 76.6 ±45.5 | 76.4 ±69.2 | 47.3 ±42.0 | 83.5 ±69.6 | |||||
| Creatine phosphokinase (U/l) | 163.0 ±93.1 | 132.2 ±68.7 | 307.5 ±355.7* | 122.1 ±70.8 | |||||
| Serum glucose (mmol/l) | 5.9 ±1.4 | 5.6 ±0.6 | 6.0 ±1.7 | 5.7 ±1.4 | |||||
| Creatinine (µmol/l) | 76.8 ±15.6 | 78.9 ±17.1 | 79.7 ±17.2 | 82.5 ±23.6 | |||||
| Glycosylated hemoglobin (%) | 5.2 ±0.8 | 4.8 ±0.9 | 5.3 ±1.2 | 5.1 ±1.0 | |||||
| Insulin (mg) | 21.7 ±10.5 | 23.6 ±11.0 | 17.1 ±9.3 | 19.7 ±11.8 | |||||
| n | % | n | % | n | % | n | % | ||
| Gender: Female | 14 | 63.6 | 13 | 56.5 | 13 | 54.2 | 11 | 47.8 | |
| Gender: Male | 8 | 36.4 | 10 | 43.5 | 11 | 45.8 | 12 | 52.2 | |
| Personal history | |||||||||
| Obesity (BMI ≥ 30 kg/m2) | 13 | 59.1 | 11 | 47.8 | 11 | 45.8 | 12 | 52.2 | |
| Overweight (BMI ≥ 25, < 30 kg/m2) | 7 | 31.8 | 9 | 39.1 | 9 | 37.5 | 8 | 34.8 | |
| Hypertension | 12 | 54.5 | 16 | 69.6 | 14 | 58.3 | 15 | 65.2 | |
| Diabetes mellitus | 8 | 36.4 | 6 | 26.1 | 10 | 41.7 | 7 | 30.4 | |
| Dyslipidaemia | 7 | 31.8 | 9 | 39.1 | 7 | 29.2 | 7 | 30.4 | |
| Smoking | 4 | 18.2 | 4 | 17.9 | 3 | 12.5 | 0 | 0.0 | |
| Family history | |||||||||
| Diabetes mellitus | 16 | 72.7 | 16 | 69.6 | 16 | 66.7 | 16 | 69.6 | |
| Dyslipidaemia | 11 | 50.0 | 15 | 65.2 | 6 | 25.0 | 6 | 26.1 | |
| Obesity | 8 | 36.4 | 12 | 52.2 | 9 | 37.5 | 6 | 26.1 | |
| Concomitant medications (CM) | |||||||||
| Patients consuming CM | 22 | 100 | 20 | 87.0 | 21 | 87.5 | 22 | 95.7 | |
| Diuretics | 4 | 18.2 | 7 | 30.4 | 7 | 29.2 | 7 | 30.4 | |
| ACEI | 9 | 40.9 | 11 | 47.8 | 9 | 37.5 | 10 | 43.5 | |
| Oral hypoglycaemic drugs | 7 | 31.8 | 1 | 4.3 | 7 | 29.2 | 4 | 17.4 | |
| Nitrovasodilator | 0 | 0.0 | 1 | 4.3 | 3 | 12.5 | 0 | 0.0 | |
| β-blockers | 4 | 18.2 | 4 | 17.9 | 3 | 12.5 | 1 | 4.3 | |
| Antiplatelet drugs | 3 | 13.6 | 2 | 8.7 | 0 | 0.0 | 1 | 4.3 | |
| Antiulcer | 1 | 4.5 | 0 | 0.0 | 2 | 8.3 | 1 | 4.3 | |
| Calcium antagonists | 2 | 9.1 | 1 | 4.3 | 2 | 8.3 | 2 | 8.7 | |
X – mean, SD – standard deviation, ACEI – angiotensin converting enzyme inhibitors.
The table includes CM consumed by ≥ 2 patients, *p < 0.05 comparison between groups (ANOVA test)
The rest of the comparisons were not significant (ANOVA test, Fisher probability exact test, p > 0.05)